Efficient Trial Design — FDA Approval of Valbenazine for Tardive Dyskinesia

A well-executed development program that addresses both regulatory and clinical requirements is critical for making novel therapeutics available as quickly as possible to patients with unmet medical needs. In the case of valbenazine, which was recently approved by the U.S. Food and Drug…

http://ift.tt/2qVj9sm